Two financings underscored capital flow into next‑generation immunotherapies. Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and first‑in‑human candidate CBX‑250, a T‑cell engager aimed at myeloid malignancies, with plans to support an IND filing this spring. In Cambridge, U.K.‑based Immutrin raised $86 million to push an antibody intended to deplete pathogenic protein deposits in amyloidosis toward clinical development; the company benefits from scientific leadership linked to founder Gregory Winter. Both rounds reflect investor interest in modalities that expand targetable antigens or address unmet needs in rare and hematologic disease.